AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01798693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-nutrient Blend
Study NCT01718379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide:10 mg per day during 21 days
Study NCT01718379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Epoetin beta: 60,000 Units/week.
Study NCT02506894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: magnesium sulfate will be given for 24 hours
Study NCT02506894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: normal saline will be given as intravenous drip over 24 hours
Study NCT00079326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00079326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00079326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04213950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rabies PEP quality improvement bundle
Description: The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
Study NCT00742053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-guided PICC placement
Description: Patients undergoing PICC placement will have ECG data collected as a function of tip location.
Study NCT04308395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib Topical Gel, 2%
Description: Patidegib Topical Gel, 2%
Study NCT03829085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EARLY ORAL REFEEDING
Description: the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
Study NCT01422096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if > 37.5 kg im once
Study NCT01182636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: 0.1% Topical Gel
Study NCT01182636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin®
Description: 0.1% Topical Gel
Study NCT01182636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel Base
Study NCT02843230 — intervention group
Intervention type: RADIATION
Intervention: Avastin
Study NCT02843230 — intervention group
Intervention type: RADIATION
Intervention: Lomustine
Study NCT02843230 — intervention group
Intervention type: RADIATION
Intervention: Temozolomide
Study NCT02843230 — intervention group
Intervention type: DEVICE
Intervention: MRI
Study NCT02843230 — intervention group
Intervention type: DEVICE
Intervention: MRS
Study NCT02843230 — intervention group
Intervention type: DEVICE
Intervention: DSC
Study NCT02099851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid body ablation (Cibiem)
Study NCT00214045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Cystoscopy
Study NCT00214045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Cystoscopy
Study NCT03655145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haplo donor stem cell transplantation
Description: The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
Study NCT03655145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HLA 10/10 MUD stem cell transplantation
Description: HLA 10/10 matched unrelated donor myeloablative transplantation
Study NCT00994552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support ventilation
Description: Pressure support ventilation
Study NCT00994552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation
Description: Pressure control ventilation
Study NCT03701958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exalt Model D Single-Use Duodenoscope
Description: Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
Study NCT02636699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250mcg
Description: Peanut extract cutaneous patch
Study NCT02636699 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
Study NCT02656017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Monitoring of tolerability and symptoms.
Study NCT02656017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monitoring of tolerability and symptoms.
Study NCT03184064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant extract (low dose)
Description: Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Study NCT03184064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Study NCT03184064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus extract (low dose)
Description: Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Study NCT03184064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant extract (high dose)
Description: Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
Study NCT03184064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant and citrus extracts (low dose / low dose)
Description: Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
Study NCT00841841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyrone and acetaminophen
Description: The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
Study NCT00259909 — intervention group
Intervention type: OTHER
Intervention: GSK questionnaire
Description: GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
Study NCT00259909 — intervention group
Intervention type: OTHER
Intervention: St. George's Respiratory Questionnaire
Description: The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
Study NCT00259909 — intervention group
Intervention type: OTHER
Intervention: Acute Short Form 12 version 2
Description: The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
Study NCT00259909 — intervention group
Intervention type: OTHER
Intervention: Global Efficacy questionnaire
Description: Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
Study NCT01828177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-320
Study NCT01828177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-320 Monad #1
Study NCT01828177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-320 Monad #2
Study NCT01828177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01260493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated health care chain
Description: Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
Study NCT03200444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 1
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy products
Study NCT03200444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 2
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy products
Study NCT03200444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 3
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy products
Study NCT03200444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-4
Description: Newly developed adhesive P-4
Study NCT03200444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-15
Description: Newly developed adhesive P-14
Study NCT03200444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-16
Description: Newly developed adhesive P-8
Study NCT02681809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin 0.0625mg
Description: Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
Study NCT02681809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin 0.125mg
Description: Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
Study NCT02681809 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: 3 sham injections approximately 1 month apart. No actual injections. No medication is used.
Study NCT01961505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical compound tripterygium
Description: Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
Study NCT01961505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
Study NCT02721940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
Study NCT02721940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mononuclear Cells
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study NCT02721940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study NCT02721940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study NCT02721940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth wristband
Description: A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth wristband
Description: A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth scale
Description: A wireless scale used by participants to measure and record daily weight.
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth scale
Description: A wireless scale used by participants to measure and record daily weight.
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA
Description: Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA
Description: Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth app
Description: A mobile application that houses study data and provides two-way messaging between the study team and study participants.
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: A mobile application that houses study data and provides two-way messaging between the study team and study participants.
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Behavior Feedback
Description: Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
Study NCT02659163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated closed-loop feedback system
Description: Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
Study NCT00589225 — intervention group
Intervention type: GENETIC
Intervention: Genetic Analysis
Description: We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
Study NCT03252769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-sampling
Study NCT02830737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional RFA
Description: Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
Study NCT02830737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch RFA
Description: Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
Study NCT02082496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: S.c. liraglutide 3.0mg once daily
Study NCT03784443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iluvien 0.19 MG Drug Implant
Description: Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
Study NCT03784443 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: Monthly PRN intravitreal injections
Study NCT03784443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: Monthly PRN intravitreal injections
Study NCT03784443 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intravitreal Injection
Description: Sham injection without penetrating needle and without drug delivery at baseline visit.
Study NCT04836052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
Study NCT02958995 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT04364477 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transversus abdominis plane (TAP) block
Description: The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
Study NCT04364477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block
Description: The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
Study NCT00168844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium Inhalation Solution
Study NCT00168844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT03590444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
Description: Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
Study NCT00591006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin (brand name Dilantin)
Description: Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
Study NCT00591006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
Study NCT00591006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
Study NCT01308541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 1
Description: Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
Study NCT01308541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LUSEDRA
Description: Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
Study NCT01308541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (arm 3)
Description: Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
Study NCT04303455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: sampling serum renin
Study NCT02438176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single trans-septal puncture
Description: The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
Study NCT02438176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bilateral groin puncture
Description: Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.